Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 14;3(3):205-213.
doi: 10.1002/bco2.129. eCollection 2022 May.

Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer

Angelyn Anton  1   2   3 , Sruti Pillai  4 , Marie Christine Semira  1 , Shirley Wong  5 , Julia Shapiro  6 , Andrew Weickhardt  4 , Arun Azad  7 , Edmond M Kwan  3   8 , Lavinia Spain  2   8 , Ashray Gunjur  4 , Javier Torres  9 , Phillip Parente  2   8 , Francis Parnis  10   11 , Jeffrey Goh  12 , Olivia Baenziger  1 , Peter Gibbs  1   5 , Ben Tran  1   7
Affiliations

Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer

Angelyn Anton et al. BJUI Compass. .

Abstract

Introduction: Several systemic therapies have demonstrated a survival advantage in metastatic castration resistant prostate cancer (mCRPC). Access to these medications varies significantly worldwide. In Australia until recently, patients must have received docetaxel first, unless unsuitable for chemotherapy, despite no evidence suggesting superiority over androgen receptor signalling inhibitors (ARSIs). Our study investigated real-world systemic treatment patterns in Australian patients with mCRPC.

Methods: The electronic CRPC Australian Database (ePAD) was interrogated to identify mCRPC patients. Clinicopathological features, treatment and outcome data, stratified by first-line systemic therapies, were extracted. Comparisons between groups utilised Kruskal-Wallis tests and Chi-Square analyses. Time-to-event data were calculated using Kaplan-Meier methods and groups compared using log-rank tests. Factors influencing overall survival (OS) and time to treatment failure (TTF) were analysed through Cox proportional hazards regression models.

Results: We identified 578 patients who received first-line systemic therapy for mCRPC. Enzalutamide (ENZ) was most commonly prescribed (n = 240, 41%), followed by docetaxel (DOC, n = 164, 28%) and abiraterone (AA, n = 100, 17%). Patients receiving ENZ or AA were older (79, 78.5 years respectively) compared with DOC (71 years, p = 0.001) and less likely to have ECOG performance status 0 (45%, 44%, 59% in ENZ, AA and DOC groups respectively p < 0.0001). Median TTF was significantly higher in those receiving ENZ (12.4 months) and AA (11.9 months) compared to DOC (8.3 months, p < 0.001). PSA50 response rates and OS were not statistically different. Time to developing CRPC > 12 months was independently associated with longer TTF (HR 0.67, p < 0.001) and OS (HR 0.49, p = 0.002).

Conclusion: In our real-world population, ENZ and AA were common first-line systemic therapy choices, particularly among older patients and those with poorer performance status. Patients receiving ENZ and AA demonstrated superior TTF compared to DOC, while OS was not statistically different. Our findings highlight the important role of ARSIs, given the variability of access worldwide.

Keywords: abiraterone; docetaxel; enzalutamide; metastatic castration‐resistant prostate cancer; real‐world data; systemic therapy.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Consort diagram—initial treatment decisions following castration‐resistance
FIGURE 2
FIGURE 2
Time to treatment failure and overall survival by first‐line therapy choice
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. - PubMed
    1. Cherny NI, Sullivan R, Torode J, Saar M, Eniu A. ESMO international consortium study on the availability, out‐of‐pocket costs and accessibility of antineoplastic medicines in countries outside of Europe. Ann Oncol. 2017;28(11):2633–47. - PMC - PubMed
    1. Chiong E, Murphy DG, Akaza H, Buchan NC, Chung BH, Kanesvaran R, et al. Management of patients with advanced prostate cancer in the Asia Pacific region: 'real‐world' consideration of results from the advanced prostate Cancer consensus conference (APCCC) 2017. BJU Int. 2019;123(1):22–34. - PubMed
    1. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy‐naive men with metastatic castration‐resistant prostate cancer (COU‐AA‐302): Final overall survival analysis of a randomised, double‐blind, placebo‐controlled phase 3 study. Lancet Oncol. 2015;16(2):152–60. - PubMed
    1. Beer TM, Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(18):1755–6. - PubMed

LinkOut - more resources